by interaction with G, cyclins in the regulation of the GI phase (Sherr, 1994) . Mutant forms of p53 no longer possess the ability to arrest cell growth and induce apoptosis (Michalovitz et al, 1990) and are unable to bind specific DNA response sequences and to activate the transcription of genes with an adjacent p53 recognition sequence (Kern et al, 1992) . Much interest was aroused by initial studies that showed that expression of p53 protein correlated with p53 gene mutations (Iggo et al, 1990) , although subsequent studies have shown that immunohistochemical expression of p53 may also occur in the absence of p53 gene mutations (Dunn et al, 1993; Kocialkowski et al, 1995; McManus et al, 1994; Nylander et al, 1995) . p53 mutations are thought to be a late event in the adenoma-carcinoma sequence in colorectal cancer (Fearon and Vogelstein, 1990) . The sensitivity of the method employed for p53 protein detection may have an important role in the sensitivity of detection of p53 using immunohistochemistry (McKee et al, 1993) . Abnormal (reduced or absent) expression of Rbl protein is thought to occur in the presence of deletions or mutations of the Rbl locus (Lemoine, 1994) . The object of this study was to examine the effect on patient prognosis of tumour p53 and Rbl expression in a large prospective unselected series of colorectal cancer.
PATIENTS AND METHODS Patients
The Gloucester Colorectal Carcinoma Study was established in 1988 by one author to examine the prognostic influence of clinicopathological factors after surgery for colonic and rectal cancer (Shepherd et al, 1995) . All patients with primary operable colorectal cancer treated at the Gloucestershire Royal Hospital are entered into this study. Each patient is regularly followed up at 6-monthly intervals with surgical outpatient assessment for a minimum of 5 years with close co-operation of general practioners. Both 'curative' and 'palliative' cases are included, although cases in which resection has been performed for metachronous carcinoma, carcinoma arising in familial adenomatous polyposis and ulcerative colitis are excluded. Cases are deemed 'curative' if the surgeon and/or pathologist believed that all tumour had been removed at the end of the surgical procedure. No patients were treated with adjuvant chemotherapy. All clinical, pathological, follow-up and survival data are entered on a computer database and regularly updated by one research officer (KJB). Survival time was calculated from the date of surgery to the date of death or last follow-up, with times censored for patients dying of causes unrelated to colorectal cancer and those surviving. Cause of death was established by autopsy or, in the absence of a post-mortem examination, by careful assessment of the clinical case records.
Pathology
All resection specimens had been meticulously examined by NAS as previously described (Shepherd et al, 1995) to assess tumour site within the colon or rectum, tumour size, tumour type (standard adenocarcinoma, mucinous or other), tumour grade (histological (Shepherd et al, 1995) . For the purposes of the current study, representative archival tumour blocks were selected for 250 consecutive patients early in the study to maximize the length of follow-up.
Immunohistochemistry
Representative blocks of formalin-fixed paraffin-embedded tumour tissue were cut at 4-jum thickness, dewaxed in xylene and then rinsed in alcohol and graded alcohol/water mixtures. A standard avidin/biotin peroxidase technique was used. Incubation with the primary p53 antibody DO-1 (Vojtesek et al, 1992 ) (Professor DP Lane, Cancer Research Campaign Molecular Oncogenesis Unit, University Of Dundee) was performed for 30 min at a dilution of 1:100. DO-1 is a well-characterized monoclonal antibody that recognizes an epitope near the N-terminus of both wild and mutant p53 proteins (Vojtesek et al, 1992) . Following incubation with the primary antibody, a secondary polyclonal biotinylated swine anti-rabbit antibody was used (Dako UK, High Wycombe, Bucks, UK). This was followed by an avidin-biotinylated peroxidase complex, with 3,3-diaminobenzidene as the chromogen. For the detection of Rbl protein, the monoclonal antibody 14,0001A was used (PharMingen, San Diego, CA, USA) at a dilution of 1 :100, followed by a secondary polyclonal biotinylated swine antirabbit antibody (Dako UK) with an avidin-biotinylated peroxidase complex, with 3,3-diaminobenzidene as the chromogen.
Scoring and interpretation of results
All sections were incubated in batches of 30-40 tumours with a tumour of known positive immunoreactivity with each run of immunostaining. Only nuclear staining of tumour nuclei was interpreted to indicate positive tumour p53 or Rbl immunoreactivity. All tumour sections were examined by DNP. The percentage of tumour nuclei staining across the whole tumour section was recorded subjectively in five categories as follows: 0%, 1-24%, 25-49%, 50-74%, 75-100%; and the grading of the intensity of immunostaining was recorded in four categories (0, 1, 2, 3), with 0 indicating no nuclear staining, 1 very weak nuclear staining, 2 intermediate nuclear staining and 3 strong nuclear staining. The score for intensity was always that of the most strongly stained 
Statistical analysis
Data were analysed using Statistica, a computer software package for a Windows IBM-compatible personal computer. The recurrence-free survival and overall survival analyses were performed using the log-rank test (Mantel, 1966) . Multivariate analyses were performed using the Cox proportional hazards model (Cox, 1972 Rbl staining appeared in univariate analysis to have reduced overall and recurrence-free survival. However, in multivariate Cox proportional hazards analysis, the prognostic effect of aberrant Rbl protein expression failed to achieve independent prognostic significance. (Iggo et al, 1990 (Dunn et al, 1993; Baas et al, 1994 Baas et al, , 1996 McManus et al, 1994; Kocialkowski et al, 1995; Nylander et al, 1995) . It has been stated that mutation of the p53 gene is one of the commonest mutations in human cancers, although mutations of p53 occur late in the adenoma-carcinoma sequence of colorectal cancer (Fearon and Vogelstein, 1990) . p53 mutations may, however, occur early in some pathways and later in other tumour types. Expression of p53 may occur in a considerable number of cases in which p53 gene mutations are not detectable by polymerase chain reaction (PCR) (Baas et al, 1994 (Baas et al, , 1996 . This again is not surprising; p53 is a normal constitutive cell cycle-associated protein, and the ability to detect p53 protein in archival formalin-fixed paraffin-embedded tissue is dependent on the sensitivity of the antigen retrieval system employed. The microwave antigen retrieval system used for detection of p53 and Rbl in the present study is quite likely to have improved the sensitivity of p53 and Rbl antigen detection (McKee et al, 1993 , British Journal of Cancer (1997 75 (1), [87] [88] [89] [90] [91] [92] [93] p53 and Rb1 protein expression in colorectal cancer 91 Remvikos et al ( Table 4 ), and most would suggest that expression of p53 is an adverse prognostic factor. The immunohistochemical evidence for a relationship between p53 expression and adverse prognosis has been corroborated either by studies of total tumour p53 or by PCR analysis of p53 gene mutations (see Table 4 ). One conflicting study showed that a group of patients with either nil or strong p53 protein expression fared worse than patients showing intermediate staining for p53 (Nathanson et al, 1994) . It has also been suggested that p53 protein expression in the cytoplasm rather than the nucleus itself may be a predictor of poor prognosis in colorectal cancer, and that nuclear p53 staining is not an adverse prognostic factor (Sun et al, 1992) . Thirty of 293 cases of colorectal carcinoma showed pure cytoplasmic p53 expression. This particular study was, however, performed with a polyclonal antibody, CM 1, and the number of cases showing pure cytoplasmic staining was small. The same authors also showed that both nuclear and p53 protein expression appeared to be important in a multivariate analysis (Sun et al, 1993) . A further study (Ofner et al, 1995) showed that there was no relationship between p53 protein expression and grade or stage parameters, such as Dukes' stage, in colorectal cancer. This finding has been reiterated (Mulder et al, 1995) in a study of 109 colorectal cancers. p53 expression was found to be more frequent in non-mucinous tumours and in metastatic tumours than in primary carcinomas. (Cance et al, 1990) .
The results from this study imply that expression of p53 and Rbl proteins does not appear to be a useful prognostic factor in colorectal cancer while coexpression of p53 and Rbl proteins is present in colorectal cancer. The apparent discrepancy of published results in the literature may to some extent reflect publication biases particularly as many studies show an effect of p53 on overall prognosis but not on other important prognostic parameters, such as tumour stage, or in subsets of particular patients in any given study but not in whole cohorts of patients.
